Next Article in Journal
Patterns of Reverse Transcriptase Inhibitor Resistance Mutations in People Living with Human Immunodeficiency Virus in Libreville, Gabon
Next Article in Special Issue
Polyparasitic Infections: Associated Factors and Effect on the Haemoglobin Level of Children Living in Lambaréné Remote and Surrounding Rural Areas from Gabon—A Cross-Sectional Study
Previous Article in Journal
Tuberculosis-Related Knowledge, Attitudes, and Practices Among Healthcare Workers in Atlantic Canada: A Descriptive Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Impact of a Community Pharmacy-Led Deworming-Related Counselling Service: An Interventional Study in a Low-to-Middle Income Country

by
Amira B. Kassem
1,*,
Ahmad Z. Al Meslamani
2,3,
Mohamed AbdElrahman
4,5,
Nadia Al Mazrouei
6,
Sherouk M. Okda
1,
Noha A. El-Bassiouny
1,
Asmaa Abdel-hamed Hamedo
7,
Doaa Abdelrazek Shaban
8,
Dina Fathy Elsmadessy
9,
Ammena Y. Binsaleh
10,
Asmaa Saleh
11 and
Hebatallah Ahmed Mohamed Moustafa
12,*
1
Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour 22514, Egypt
2
College of Pharmacy, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates
3
AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates
4
College of Pharmacy, Al-Mustaqbal University, Babylon 51001, Iraq
5
Clinical Pharmacy Department, Badr University Hospital, Faculty of Medicine, Helwan University, Helwan 11795, Egypt
6
Department of Pharmacy Practice and Pharmacotherapeutics at College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates
7
Beheira Specialized Children’s Hospital, Beheira 11588, Egypt
8
Sanhour Health Unit, Damnhour, Beheira 22516, Egypt
9
Vaccination Department, Elmahmoudeia Health Unit, Elmahmoudeia, Beheira 22753, Egypt
10
Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
11
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
12
Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Badr University in Cairo, Cairo 11829, Egypt
*
Authors to whom correspondence should be addressed.
Trop. Med. Infect. Dis. 2025, 10(8), 215; https://doi.org/10.3390/tropicalmed10080215
Submission received: 27 June 2025 / Revised: 24 July 2025 / Accepted: 29 July 2025 / Published: 30 July 2025

Abstract

Background: Since the current increase in antimicrobial resistance globally, parasitic infectious diseases have become a greater public health crisis than ever before and an absolute priority. The Egyptian community pharmacist, as a health care provider and advisor, has a potential role to play in deworming. Objective: To evaluate the outcomes of community pharmacist-led deworming-related counseling services. Methods: A prospective randomized controlled study was conducted in Damanhur, Behera, Egypt. The intervention group received community pharmacy counseling, and the control group received the usual care. Both groups were monitored for 12 months for recurrence evaluation. Results: A total of 173 patients were included, of whom 96 (55.5%) received patient counseling. The types of infection included Oxyuris (44.5%), Entamoeba histolytica (28.9%), Ascaris (8.7%), Entamoeba Cyst (8.7%), Giardiasis (4.6%), Schistosomiasis (2.9%), and pinworm (1.7%). A total of 119 participants (68.8%) reported a need for dose repetition. Personal hygiene practices were reported by 71 participants (41%). Recurrence of infection was observed in 101 cases (58.4%). Patient counseling was significantly associated with lower recurrence rates and higher rates of personal hygiene application (p < 0.001). Multivariate logistic regression analysis revealed that patient counseling and personal hygiene measures were the only significant predictors of infection recurrence rate. Conclusions: Community pharmacists’ deworming-related counseling had positive behavioral and clinical outcomes.

1. Introduction

1.1. Introduction to Parasitic Diseases

Parasitic diseases, such as protozoal infections and worms, are among the neglected tropical diseases designated by the World Health Organization (WHO) because their surveillance, prevention, and treatment are often neglected [1,2,3]. Parasitic diseases continue to increase global mortality and the economic burden [4,5,6,7], especially in low-to-middle-income countries (LMICs) among illiterate populations and settings with poor sanitation [4,8,9,10].
Although there is a global dependence on drug donations of chemotherapy for neglected tropical disease (NTD) control [11,12], endemic countries still have insufficient breaks of transmission [13,14]. The development of novel antiparasitic drugs and the use of drug combinations need to be envisioned to address the potential resistance [15,16,17] that may be aggravated by using generic substandard anthelmintic drugs [18].
Parasitic disease management over the past few decades posed a tremendous challenge in Egypt [8,19]. In the era of “One Health” and emerging resistance to all antimicrobial agents, Egypt intends to combat parasitic infections and develop effective prevention strategies, where the Egyptian community pharmacist has a potential role to play [19,20,21,22,23]. The effectiveness of available deworming drugs is compromised by emerging drug resistance, cross-resistance, and lower-than-needed novel drug development [15,18]. The WHO Road Map for NTDs supports endemic countries to implement mass anthelmintic treatment, especially for children and child-bearing-age women (who are not in the first trimester of pregnancy) [14,24,25,26], and to overcome barriers to diagnosis and prevention of parasitic infections [27].

1.2. Parasites

Parasites are microorganisms that live on or inside a host and benefit at the expense of this host [28]. Medically relevant parasites include a diverse array of microorganisms, such as protozoa, helminths, and ectoparasites [29]. They cause debilitating disability and are often stigmatized [30]. They are particularly common in poor communities [8,19]. Healthcare providers should consider the risk of infection in subjects living in or traveling to endemic areas [31].

1.3. Protozoa

Protozoa are microscopic unicellular organisms that contribute enormously to the infectious disease burden worldwide [2,32,33]. They include Giardia intestinalis, Cryptosporidium spp., and Entamoeba histolytica [21]. Protozoal infections are highly prevalent in LMICs, especially in rural areas and among those living in crowded urban environments. Causes of protozoal infections include poor sanitization, lack of clean water access, low socioeconomic conditions, and living close to carriers [2]. Protozoan infections range from asymptomatic to fatal. The health of the host plays a role in the spread of infection. Carriers’ defense systems can control, but not eliminate, an infection [15]. Dormant cysts in the life cycle of protozoa survive in difficult conditions for a long period with no oxygen, water, or nutrients [15]. The effectiveness of antiprotozoal drugs is diminished due to resistance development, the emergence of cross-resistance, and the lack of vaccines [15,21].
Entamoeba histolytica is an invasive pathogenic intestinal amoeba protozoan [34]. Amoebas are protozoa that use their pseudopodia for movement and may cause dysenteric liver abscesses [32,33]. Many of the individuals infected with Entamoeba histolytica are asymptomatic [35,36]. Factors related to the host, such as gene expression, play a role in invasive amebiasis [37,38]. Invasion may be accompanied by inflammatory tissue damage, and the leptin signalling activity may confer resistance to Entamoeba histolytica [39]. In addition, oxidative stress may enhance the parasite viability by suppressing gene expression [40]. Genes associated with Entamoeba histolytica’s virulent phenotype include STIRP, which plays a role in the interaction of the amoeba with
Target cells [41]. Amoebiasis can be diagnosed immunologically using a patient’s stool or blood [42] or by molecular biology techniques, which can differentiate the pathogenic entamoeba from other harmless species that look similar under microscopy [34,43]. Five-NI drugs, such as metronidazole, tinidazole, secnidazole, and ornidazole, are the mainstay of amoebiasis treatment [21]. Intestinal amoebiasis treatment failure occurs mostly due to recurring infection, rather than drug resistance [44,45]. However, lower drug susceptibility was also reported [46].

1.4. Heliminths

Helminths are multi-cellular parasitic worms [25,29]. They include nematodes (roundworms, e.g., Ascaris lumbricoides, and oxyuris), trematodes (flatworms/flukes, e.g., Schistosoma), and cestodes (tapeworms) [5,8,25,47]. Soil-transmitted helminthiasis (STHs), or geo-helminths, include hookworm (Necator americanus and Ancyclostoma duodenale), roundworm (Ascaris), and whipworm [25,48,49]. Contaminated soil plays a big role in their transmission. Eggs are deposited through feces in the local environment via open defecation, using soil for cleansing hands, or poor hygiene after defecating. The eggs then undergo molting in the soil before re-entering the human host. Helminths cannot reproduce within their hosts [25,50]. SHT transmission occurs via skin penetration, accidental ingestion, or a vector bite [25].
Most of the worms live in warm and moist geographic regions (tropics and subtropics) [51]. Countries with high standards of environmental and home hygiene, such as Japan, are free from worm infestations nowadays [52]. Most worm infections are mild and asymptomatic. Moderate to heavy helminth infestations may be associated with nutritional compromise (mainly fats and vitamins), enteropathy (diarrhea, abdominal pain, malaise, weakness, anorexia), growth faltering, impaired cognitive function, and poor academic performance among children [4,25,53,54,55].
Molecular-based approaches, such as PCR (both traditional and real-time), are newer techniques used to detect several helminth infections [56]. Commonly used deworming drugs include albendazole, mebendazole, and praziquantel. They are safe and efficacious against a variety of worm infestations [48]. Stool microscopy is used to identify helminths [27]. Improving the health outcomes for individuals suffering from these illnesses is multifaceted. Improved access to water, sanitation, and hygiene is also recommended in the sustainable development goals [57].

1.5. Preventive Measures Against Parasitic Infections

The adoption of effective preventive measures and the provision of individualized therapy are highly warranted [27]. The key factors underpinning parasitic infections are poverty, overcrowding, poor water supply, inadequate food hygiene, open defecation, and warm climate. Key drivers of improving personal and environmental hygiene, such as eliminating open defecation, proper hand washing after toileting, proper sanitation, changing underwear regularly, cutting nails, proper washing and drying of clothes, bed sheets, and toys, maintaining a clean kitchen, and using food utensils for eating, should be promoted while counseling the members of the family. Family members and housekeeping staff should receive prophylactic treatment to prevent person-to-person transmission [27,49,51].

1.6. Challenges of Parasitic Infections Management and Role of the Pharmacist

Parasitic infections often lead to physical, social, and economic burdens [58]. Adherence to deworming drugs is usually low due to their severe adverse reactions [59]. The resistance to deworming medications is widespread and increasing [15,21,60]. Because many of the drugs used are uncommon [12], coordination between the physician and the pharmacist is crucial.
The pharmacist is an integral part of the healthcare workforce [61,62,63,64]. Community pharmacists have the advantage of the flexibility of appointments, as patients receive one consultation rather than have to visit multiple providers to receive the same service [65,66,67]. The expansion of community pharmacy-based services has driven the majority of the public to perceive them as public health actors [31,58,61,68,69]. Because of their experience and knowledge, community pharmacists can treat minor ailments and ensure optimal care [67,70,71,72,73,74]. The community pharmacist has a pivotal role in monitoring, managing antimicrobial resistance, informing patients, and avoiding deworming drug misuse [60,75].
Parasitic diseases are a challenging specialty, requiring up-to-date knowledge of drug resistance and both international and local health regulations. Because tropical medicine is mainly focused on preventive health care, the patient’s health will depend on the healthcare practitioner’s expertise and proficiency in providing counseling. The community pharmacist can also reinforce the use of recommended hygiene measures [76,77,78,79]. The expansion of the scope of practice of community pharmacists with training would further improve patients’ access to optimal care at community pharmacies. Of note, in some countries, pharmacists with certain qualifications can independently prescribe within the scope of their specialty [67,80,81]. However, without an adequate competent workforce running an already busy pharmacy, it would be challenging to maintain the workflow and incorporate the new specialized service into their workload [67,82].
Notably, intensive collaboration between the prescribers and community pharmacists is needed to ensure optimal care, and providing the community pharmacists with the required appropriate training can ensure the proper implementation of WHO health guidelines and accelerate progress toward sustainable development’s healthcare goals [83]. Including the pharmacist in an interprofessional team helps to drive better outcomes in endemic regions [75,84]. Based on the above, the community pharmacist has a potential role to play in advising and counseling patients with parasitic infections. To the best of our knowledge, there has not been a study that evaluates the community pharmacists-led services regarding the management of parasitic diseases. Therefore, this study aims to evaluate the impact of community pharmacist-led patient counseling services regarding applying proper personal hygiene, preventing the recurrence of parasitic infection, and reducing the need for dose repeat

2. Patients and Methods

2.1. Study Design and Setting

This was an open-label randomized clinical trial (RCT) involving 173 patients from Damanhur, Behera, Egypt, collected from community pharmacies. Participants were randomly assigned to either the intervention group (n = 96) or the control group (n = 77), resulting in an allocation ratio of approximately 1.25:1. There were no exclusion criteria for patients. The data for every patient was collected in a Google form, including sex, age, weight, type of infection, and drug administered. The intervention group received one face-to-face counseling session outside the dispensing area in a private consultation area in the pharmacy during a specific appointment to ensure the quality of care and two mobile-phone follow-up counseling sessions about drug use, along with non-pharmacological hygiene measures. The primary endpoint of this study is the reduction in the recurrence rate of parasitic infections after 12 months. At the end of this 12-month study, both the need for a dose repeat and adherence to personal hygiene were directly assessed by questioning the patient.

2.2. Recruitment

Community-pharmacist-led services were promoted by contacting the patients, using posters and flyers, and referral by local physicians. A standardized training program was conducted for the pharmacists involved in the intervention group prior to the study. This training focused on consistent delivery of counseling content, including drug use, hygiene practices, and adherence strategies, based on a prepared counseling protocol. To avoid bias, different pharmacists were assigned to the intervention and control groups. Those providing counseling services were not involved in dispensing medications to the control group participants.

2.3. Randomization

An online tool for randomization was used to reduce selection bias [85].

2.4. Intervention

In addition to the conventional community pharmacist services (supply of medications), the community pharmacist gave the proper patient counseling about the prescribed anthelminthic, including the correct dose and duration. They also provided patients with information on the importance of non-pharmacological measures, such as personal hygiene. To reinforce messages and monitor progress, two telephone calls were scheduled: in Call 1 (week 2), the community pharmacist verified treatment initiation, checked for adverse effects, solved practical barriers (e.g., reminder tools), and reiterated key hygiene behaviours. In Call 2 (week 8), the community pharmacist assessed completion of therapy, reviewed persistence of hygiene practices, screened for recurrent symptoms, and reminded patients of the 12-week stool-analysis appointment. Of the 96 participants in the intervention group, 90 (93.8%) completed both calls, 4 (4.2%) completed one call, and 2 (2.1%) could not be reached despite three attempts and, therefore, received no follow-up call.
These services were provided in a designated patient counseling area inside the community pharmacy. After that, the patients were followed up to promote adherence to medication and hygiene measures and to determine the impact of patient counseling on reinfection. Hygiene practices were measured at two time points: at baseline (pre-intervention) and at follow-up (12 weeks post-intervention). Personal hygiene practices were assessed using a structured, self-administered checklist comprising eight items, including:
  • washing hands with soap and water after using the toilet;
  • washing hands with soap and water before and after eating;
  • trimming fingernails regularly;
  • drinking clean, safe water (filtered/boiled/bottled);
  • changing and washing bed sheets regularly;
  • washing fruits and vegetables thoroughly before eating;
  • defecating in a sanitary toilet, not performing open defecation;
  • educating my children/family members about handwashing and hygiene
Participants were asked to indicate whether they practiced each behavior consistently (“Yes”/”No”) during the study period. The score was then converted into a binary outcome (adequate vs. inadequate hygiene) for analysis. The pharmacists provided counseling services at a dedicated time outside the conventional dispensing time under a pharmacist–physician collaborative protocol. Recurrence was measured based on self-reported symptoms and repeated stool analysis.
Outcome measures are defined as follows: recurrence, defined as self-reported gastrointestinal symptoms consistent with the baseline infection and laboratory confirmation of the same parasite species within 12 months; adequate hygiene, defined as affirmative (“Yes”) responses to ≥6 of the 8 checklist items at the 12-week assessment; and dose repeat, defined as receipt of an additional anthelmintic dose after completion of the initial course, documented in pharmacy records or self-report. These binary outcomes (Yes/No) were used in all subsequent analyses.

2.5. Sample Size Calculation

The sample size for this trial was calculated to determine the effect of patient counseling on adopting personal hygiene measures and reducing the recurrence rates of parasitic infections in Egypt. The primary endpoint of this study is the reduction in the recurrence rate of parasitic infections after 12 months.
To estimate the necessary sample size, we adopted Rosner’s equations, in which we assumed a two-sided significance level (α) of 0.05 and a power (β) of 80% (power = 0.80). Based on previous studies, the recurrence rate of parasitic infections without intervention is approximately 30% (p1 = 0.30). We aim to achieve a clinically meaningful reduction of 10% in recurrence rates with counseling, bringing the rate down to 20% (p2 = 0.20). The calculated sample size required for each group (intervention and control) to achieve a 10% reduction in the recurrence rate of parasitic infections with 80% power and a 5% significance level is approximately 62 participants. Therefore, a total of 124 participants (62 in each group) would be required for this study. However, in this study, we were able to secure 77 controls and 96 participants in the intervention group.
Rosner’s equations:
N 1 =   Z 1 α 2 p ¯ q ¯ ( 1 + 1 k ) ̄ + z 1 β *   p 1 q 1 + ( p 2 q 2 k ) ̄ 2 / Δ 2
q 1 = 1 p 1
q 2 = 1 p 1
p ¯ = p 1 + k p 2 1 + k
q ¯ = 1 p ¯
N 1 = 1.96 0.2 0.8 ( 1 + 1 1 ) ̄ + 0.84 * 0.3 0.7 + ( 0.1 0.9 1 ) ̄   2 / 0.2 2
N 1 = 62
N 2 = k * N 1 = 62
where
p1 and p2 represent the proportions (incidences) of groups 1 and 2, respectively.
Δ denotes the absolute difference between the two proportions, calculated as |p2 − p1|.
n1 is the sample size for group 1.
n2 is the sample size for group 2.
α indicates the probability of making a Type I error, typically set at 0.05.
β indicates the probability of making a Type II error, commonly set at 0.2.
z represents the critical Z value corresponding to a given α or β.
K is the ratio of the sample size of group 2 to that of group 1.

2.6. Statistical Analysis

SPSS version 27 was used for data analysis. All variables were categorical and presented as numbers with percentages. In addition to descriptive analysis, the chi-square test was used to test differences in recurrence rates across other variables. Logistic regression was conducted to evaluate the associated factors with the infection recurrence rate. A p-value of less than 0.05 was considered significant.

3. Results

The study included 173 patients, of whom 51 (29.5%) were over 18 years old (Table 1). Regarding gender, females represented a higher proportion with 92 participants (53.2%). The types of infection observed were predominantly Oxyuris with 77 cases (44.5%), followed by Entamoeba with 50 cases (28.9%), Ascaris with 15 cases (8.7%), Entamoeba Cyst with 15 cases (8.7%), Giardia with 8 cases (4.6%), Schistosomiasis with 5 cases (2.9%) and Pinworm with 3 cases (1.7%). Personal hygiene practices were reported by 71 participants (41%). Among the participants, 96 (55.5%) received patient counseling. Regarding dose repetition, 119 participants (68.8%) reported a need for dose repetition, while 54 participants (31.2%) did not. Finally, recurrence of infection was observed in 101 cases (58.4%). As shown in Figure 1, Albendazole (71, 41.04%) was the most commonly used drug, followed by Metronidazole (59, 34.10%) and Flubendazole (23, 13.29%).
The findings showed that gender and dose repetition were not statistically significant factors affecting recurrence rates (p < 0.05). The recurrence of parasitic infections was highest in children aged 6–11 years (p < 0.05). Patients infected with Entamoeba and Oxyuris showed relatively high recurrence rates, whereas those with Schistosomiasis, Giardia, and Pinworm infections had lower or no recurrence (p < 0.05). Personal hygiene practices were significantly increased (p < 0.001), and recurrence rates were significantly reduced (p < 0.001) with community-pharmacist-provided patient counseling (Table 2 and Table 3).
Those not adhering to personal hygiene had a much higher recurrence rate (83.3%) compared to those practicing hygiene (22.5%). Similarly, patient counseling showed a significant impact, with 93.5% recurrence in patients who did not receive counseling versus 30.2% in those who did, as shown in Figure 2.
Logistic regression was conducted to assess factors affecting the recurrence rate. In univariate logistic regression analysis, the age group > 18 years showed statistically significant lower odds of recurrence (OR = 0.203, p < 0.001), as did the 0–5 year group (OR = 0.389, p = 0.037), compared to the reference age group of 6–11 years. Moreover, patient counseling was significantly associated with a lower risk of recurrence (OR = 0.03, p < 0.001). Similarly, adherence to personal hygiene measures also reduced the risk of recurrence (OR = 0.058, p < 0.001).
Regarding the type of infection, none of the specific parasites (including Entamoeba, Ascaris, Oxyuris, Giardia, and Pinworm) showed a statistically significant association with recurrence in the univariate and multivariate models when compared to the reference group (Schistosomiasis), despite some showing high odds ratios. Other variables, such as gender and repeated doses of medication, were not significantly associated with infection recurrence in either analysis.
After adjusting for age, gender, and infection type in the multivariate logistic regression model, patient counseling and personal hygiene measures were the only significant predictors of the infection recurrence rate (p < 0.01), as shown in Table 4.

4. Discussion

In this prospective open-label randomized control study of adults and children from a low-to-middle-income country (LMIC) receiving counseling for deworming, we found that community pharmacist-provided patient counseling was significantly associated with lower recurrence rates and higher rates of application of personal hygiene practices.
Although there was a safe water source in the region where the study was performed, other factors may promote parasitic infections, such as poor hygiene measures, consuming raw food, and walking barefoot [86,87]. Oxyuris and Entamoeba were the most prevalent infections in our study sample. The parasite species identified in two previous studies included Ascaris, Oxyuris, Entamoeba, and Giardia species [88,89].
Indiscriminate use of antiparasitic drugs is a matter of concern in LMIC, regardless of the socioeconomic or educational level of the population [90,91]. More than half of our sample were females. We did not find a significant gender-based difference concerning the rate of recurrence. Girls and women are more difficult populations to reach in LMICs [92].
Nearly two-thirds of our patients were pediatric and most of the infections were helminth infections. Helminth infections are more frequent in pediatric patients and may lead to resistance to medication and reinfection in adulthood [34]. Nearly 3% of patients in this study were infected with Schistosoma, which is highly prevalent in the Beheira governorate [8]. The recreational swimming behavior of children in canals in rural areas has greatly decreased over the last decades, which has decreased the spread of infection [93].
Drug administration can reduce morbidity. However, it is unlikely to interrupt transmission by itself due to reinfection [94]. Reinfection with helminth after treatment is the norm [95,96]. The use of any antimicrobial agent, including deworming medications, should be meticulously monitored to minimize the emergence of resistance [21,59]. This highlights the role of supporting drug administration with patient counseling and improved hygiene in ensuring the successful elimination of parasitic infections [97]. Supporting a shift from control to elimination is a challenge that requires strategic research and action [98].
Community pharmacists are in a good position to provide healthcare services because of their accessibility [31]. In addition to their roles as drug professionals, community pharmacists can play a role in the management of infectious diseases through their healthcare advice and patient counseling activities [83]. Previous studies reported high levels of patient satisfaction with pharmacist-led healthcare services [99,100,101]. It is the responsibility of the community pharmacist as a health promoter to inform, educate, and counsel patients about the management of these parasitic diseases and the risks associated with drug misuse and drug resistance [102,103]. We found that community pharmacist-provided patient counseling significantly reduced parasitic infection recurrence rates, in line with a previous study [104]. Increasing patients’ awareness of community pharmacy services and promoting collaboration with physicians was previously recommended in the literature [105]. The community pharmacists in this study provided counseling services under a pharmacist–physician collaborative protocol.
We acknowledge the sample size is relatively small and that our study was not blinded. However, the current study has some points of strength, given the limited published literature on the topic. The study found that dedicated counseling services provided by community pharmacists to patients with parasitic diseases significantly promoted good hygiene and reduced parasitic infection recurrence.
The deworming service is complex and requires sufficient staffing, resources, time dedicated to the service, laboratory access, further training, ongoing teamwork communication, and logistical considerations to ensure optimal, accessible, and convenient care. Nevertheless, this study showed that there is scope for better improvements to ensure community pharmacy-led health services are providing optimum care. It is recommended that the impact of a specific deworming continuing professional development training program on community pharmacists be studied.

5. Conclusions

This trial showed that pharmacist-delivered counseling, reinforced by diligent personal hygiene, decisively curtailed the recurrence of parasitic infections, whereas age in early school years posed the greatest risk and adulthood offered the lowest. Counselling and hygiene emerged as the only independent predictors of sustained clearance in multivariate analysis; gender, parasite species, and repeat dosing did not materially influence outcomes. These findings highlight the pivotal role of community pharmacists in coupling medication guidance with behavior-based prevention strategies to break the reinfection cycle in resource-constrained settings.

Author Contributions

Conceptualization, A.Z.A.M. and A.B.K.; methodology, A.S., A.Y.B., N.A.E.-B., S.M.O. and A.A.-h.H.; software, M.A. and D.F.E.; validation, N.A.M. and D.A.S.; formal analysis, A.Z.A.M. and S.M.O.; investigation, N.A.E.-B.; resources, N.A.M.; data curation, D.F.E. and D.A.S.; writing—original draft preparation, H.A.M.M., A.A.-h.H. and D.A.S.; writing—review and editing, H.A.M.M. and A.B.K.; visualization, H.A.M.M., A.A.-h.H. and D.A.S.; supervision, A.Z.A.M. and M.A.; project administration, A.B.K., H.A.M.M. and N.A.E.-B.; funding acquisition, A.Y.B. and A.S. All authors have read and agreed to the published version of the manuscript.

Funding

The current work was supported by Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2025R419), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

Institutional Review Board Statement

This research was approved by the Research Ethical Committee (REC), at Badr University in Cairo, Egypt, number (BUC-IACUC-240418-85) on 18 April 2024. The study was conducted in accordance with the Declaration of Helsinki.

Informed Consent Statement

Written informed consent has been obtained from the patients to publish this paper.

Data Availability Statement

Availability of Data and Materials: Data are available from the corresponding author (H.A.M.M) upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bockarie, M.J.; Kelly-Hope, L.A.; Rebollo, M.; Molyneux, D.H. Preventive Chemotherapy as a Strategy for Elimination of Neglected Tropical Parasitic Diseases: Endgame Challenges. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013, 368, 20120144. [Google Scholar] [CrossRef]
  2. Kumar, V.; Bhargava, G. Editorial: Protozoal Infections: Treatment and Challenges. Front. Cell. Infect. Microbiol. 2022, 12, 1002602. [Google Scholar] [CrossRef] [PubMed]
  3. World Health Organization. Guideline: Preventive Chemotherapy to Control Soil-Transmitted Helminth Infections in at-Risk Population Groups; World Health Organization: Geneva, Switzerland, 2017; ISBN 978-92-4-155011-6. [Google Scholar]
  4. de Silva, N.R.; Brooker, S.; Hotez, P.J.; Montresor, A.; Engels, D.; Savioli, L. Soil-Transmitted Helminth Infections: Updating the Global Picture. Trends Parasitol. 2003, 19, 547–551. [Google Scholar] [CrossRef]
  5. Hamory, J.; Miguel, E.; Walker, M.; Kremer, M.; Baird, S. Twenty-Year Economic Impacts of Deworming. Proc. Natl. Acad. Sci. USA 2021, 118, e2023185118. [Google Scholar] [CrossRef] [PubMed]
  6. Leslie, J.; Garba, A.; Boubacar, K.; Yayé, Y.; Sebongou, H.; Barkire, A.; Fleming, F.M.; Mounkaila, I.; Adamou, S.; Jackou, M.L.B. Neglected Tropical Diseases: Comparison of the Costs of Integrated and Vertical Preventive Chemotherapy Treatment in Niger. Int. Health 2013, 5, 78–84. [Google Scholar] [CrossRef] [PubMed]
  7. Stephenson, L.S.; Latham, M.C.; Ottesen, E.A. Malnutrition and Parasitic Helminth Infections. Parasitology 2000, 121, S23–S38. [Google Scholar] [CrossRef]
  8. Abou-El-Naga, I.F. Towards Elimination of Schistosomiasis after 5000 Years of Endemicity in Egypt. Acta Trop. 2018, 181, 112–121. [Google Scholar] [CrossRef]
  9. Dantas-Torres, F.; Otranto, D. Dogs, Cats, Parasites, and Humans in Brazil: Opening the Black Box. Parasites Vectors 2014, 7, 22. [Google Scholar] [CrossRef]
  10. Zegeye, B.; Keetile, M.; Ahinkorah, B.O.; Ameyaw, E.K.; Seidu, A.-A.; Yaya, S. Utilization of Deworming Medication and Its Associated Factors among Pregnant Married Women in 26 Sub-Saharan African Countries: A Multi-Country Analysis. Trop. Med. Health 2021, 49, 53. [Google Scholar] [CrossRef]
  11. Holt, F.; Gillam, S.J.; Ngondi, J.M. Improving Access to Medicines for Neglected Tropical Diseases in Developing Countries: Lessons from Three Emerging Economies. PLoS Neglected Trop. Dis. 2012, 6, e1390. [Google Scholar] [CrossRef]
  12. Lin, W.M.; Addiss, D.G. Sustainable Access to Deworming Drugs in a Changing Landscape. Lancet Infect. Dis. 2018, 18, e395–e398. [Google Scholar] [CrossRef]
  13. Brooker, S.J.; Nikolay, B.; Balabanova, D.; Pullan, R.L. Global Feasibility Assessment of Interrupting the Transmission of Soil-Transmitted Helminths: A Statistical Modelling Study. Lancet Infect. Dis. 2015, 15, 941–950. [Google Scholar] [CrossRef]
  14. Villacorta Linaza, R.; Garner, T.; Genovezos, C. Building Supply Chain Capacity for Neglected Tropical Diseases: Experience from the Ascend West and Central Africa Programme. Trans. R. Soc. Trop. Med. Hyg. 2021, 115, 841–846. [Google Scholar] [CrossRef]
  15. Capela, R.; Moreira, R.; Lopes, F. An Overview of Drug Resistance in Protozoal Diseases. Int. J. Mol. Sci. 2019, 20, 5748. [Google Scholar] [CrossRef]
  16. Geary, T.G. Are New Anthelmintics Needed to Eliminate Human Helminthiases? Curr. Opin. Infect. Dis. 2012, 25, 709–717. [Google Scholar] [CrossRef] [PubMed]
  17. Hotez, P.J. Global Deworming: Moving Past Albendazole and Mebendazole. Lancet Infect. Dis. 2017, 17, 1101–1102. [Google Scholar] [CrossRef]
  18. Suleman, S.; Zeleke, G.; Deti, H.; Mekonnen, Z.; Duchateau, L.; Levecke, B.; Vercruysse, J.; D’Hondt, M.; Wynendaele, E.; De Spiegeleer, B. Quality of Medicines Commonly Used in the Treatment of Soil Transmitted Helminths and Giardia in Ethiopia: A Nationwide Survey. PLoS Negl. Trop. Dis. 2014, 8, e3345. [Google Scholar] [CrossRef] [PubMed]
  19. Eassa, S.M.; Abd El-Wahab, E.W. Vector-Borne Diseases in Egypt: Present Status and Accelerating toward Elimination. J. Vector Borne Dis. 2022, 59, 127–138. [Google Scholar] [CrossRef] [PubMed]
  20. Aslam, B.; Khurshid, M.; Arshad, M.I.; Muzammil, S.; Rasool, M.; Yasmeen, N.; Shah, T.; Chaudhry, T.H.; Rasool, M.H.; Shahid, A.; et al. Antibiotic Resistance: One Health One World Outlook. Front. Cell. Infect. Microbiol. 2021, 11, 771510. [Google Scholar] [CrossRef]
  21. El-Taweel, H.A. Understanding Drug Resistance in Human Intestinal Protozoa. Parasitol. Res. 2015, 114, 1647–1659. [Google Scholar] [CrossRef]
  22. One Health. Available online: https://www.who.int/news-room/fact-sheets/detail/one-health (accessed on 3 January 2024).
  23. Moustafa, H.A.M.; Wen, M.M.; AbdElrahman, M.; Hamdan, A.M.E.; Alkhamali, A.; Kassem, A.B. Psychological Challenges Faced Community Pharmacists during COVID-19 Pandemic: A Cross-Sectional Study. Pharm. Pr. 2025, 23, 1–10. [Google Scholar] [CrossRef]
  24. Ending the Neglect to Attain the Sustainable Development Goals: A Rationale for Continued Investment in Tackling Neglected Tropical Diseases 2021–2030. Available online: https://www.who.int/publications-detail-redirect/9789240052932 (accessed on 3 January 2024).
  25. Jourdan, P.M.; Lamberton, P.H.L.; Fenwick, A.; Addiss, D.G. Soil-Transmitted Helminth Infections. Lancet 2018, 391, 252–265. [Google Scholar] [CrossRef] [PubMed]
  26. Truscott, J.E.; Turner, H.C.; Anderson, R.M. What Impact Will the Achievement of the Current World Health Organisation Targets for Anthelmintic Treatment Coverage in Children Have on the Intensity of Soil Transmitted Helminth Infections? Parasites Vectors 2015, 8, 551. [Google Scholar] [CrossRef]
  27. Bharti, B.; Bharti, S.; Khurana, S. Worm Infestation: Diagnosis, Treatment and Prevention. Ind. J. Pediatr. 2018, 85, 1017–1024. [Google Scholar] [CrossRef]
  28. Doherty, J.-F.; Milotic, M.; Filion, A.; Eriksson, A. Host Specificity and the Reproductive Strategies of Parasites. Parasitology 2022, 149, 534–541. [Google Scholar] [CrossRef]
  29. Theel, E.S.; Pritt, B.S.; Hayden, R.T.; Wolk, D.M.; Carroll, K.C.; Tang, Y.-W. Parasites. Microbiol. Spectr. 2016, 4, 411–466. [Google Scholar] [CrossRef] [PubMed]
  30. Bennis, I.; De Brouwere, V.; Belrhiti, Z.; Sahibi, H.; Boelaert, M. Psychosocial Burden of Localised Cutaneous Leishmaniasis: A Scoping Review. BMC Public Health 2018, 18, 358. [Google Scholar] [CrossRef]
  31. Kc, B.; Alrasheedy, A.A.; Leggat, P.A.; Mohamed Ibrahim, M.I.; Christopher, C.M.; Sapkota, B.; Shrestha, S. Types and Outcomes of Pharmacist-Managed Travel Health Services: A Systematic Review. Travel Med. Infect. Dis. 2023, 51, 102494. [Google Scholar] [CrossRef]
  32. Fletcher, S.M.; Stark, D.; Harkness, J.; Ellis, J. Enteric Protozoa in the Developed World: A Public Health Perspective. Clin. Microbiol. Rev. 2012, 25, 420. [Google Scholar] [CrossRef] [PubMed]
  33. Shanan, S.; Abd, H.; Bayoumi, M.; Saeed, A.; Sandström, G. Prevalence of Protozoa Species in Drinking and Environmental Water Sources in Sudan. BioMed Res. Int. 2015, 2015, 1–5. [Google Scholar] [CrossRef]
  34. Costa, J.D.O.; Resende, J.A.; Gil, F.F.; Santos, J.F.G.; Gomes, M.A. Prevalence of Entamoeba Histolytica and Other Enteral Parasitic Diseases in the Metropolitan Region of Belo Horizonte, Brazil. A Cross-Sectional Study. Sao Paulo Med. J. 2018, 136, 319–323. [Google Scholar] [CrossRef] [PubMed]
  35. Elswaifi, S.F.; Palmieri, J.R.; El-Tantawy, N.; El-Hussiny, M.; Besheer, T.; Abohashem, E. Comparison of Microscopic and Immunoassay Examination in the Diagnosis of Intestinal Protozoa of Humans in Mansoura, Egypt. J. Parasit. Dis. 2016, 40, 580–585. [Google Scholar] [CrossRef]
  36. Stanley, S.L., Jr. Amoebiasis. Lancet 2003, 361, 1025–1034. [Google Scholar] [CrossRef]
  37. Haque, R.; Faruque, A.S.; Hahn, P.; Lyerly, D.M.; Petri, W.A. Entamoeba Histolytica and Entamoeba Dispar Infection in Children in Bangladesh. J. Infect. Dis. 1997, 175, 734–736. [Google Scholar] [CrossRef] [PubMed]
  38. Thibeaux, R.; Weber, C.; Hon, C.-C.; Dillies, M.-A.; Avé, P.; Coppée, J.-Y.; Labruyère, E.; Guillén, N. Identification of the Virulence Landscape Essential for Entamoeba Histolytica Invasion of the Human Colon. PLoS Pathog. 2013, 9, e1003824. [Google Scholar] [CrossRef] [PubMed]
  39. Faust, D.M.; Guillen, N. Virulence and Virulence Factors in Entamoeba histolytica, the Agent of Human Amoebiasis. Microbes Infect. 2012, 14, 1428–1441. [Google Scholar] [CrossRef]
  40. Yanagawa, Y.; Sharma, M.; Izumiyama, S.; Singh, U. Exploring Virulence and Stress Response in Entamoeba histolytica: Insights from Clinical Strains. Microbiol. Spectr. 2025, 13, e0050625. [Google Scholar] [CrossRef]
  41. MacFarlane, R.C.; Singh, U. Identification of an Entamoeba Histolytica Serine-, Threonine-, and Isoleucine-Rich Protein with Roles in Adhesion and Cytotoxicity. Eukaryot. Cell 2007, 6, 2139–2146. [Google Scholar] [CrossRef]
  42. Haque, R.; Mollah, N.U.; Ali, I.K.; Alam, K.; Eubanks, A.; Lyerly, D.; Petri, W.A. Diagnosis of Amebic Liver Abscess and Intestinal Infection with the TechLab Entamoeba Histolytica II Antigen Detection and Antibody Tests. J. Clin. Microbiol. 2000, 38, 3235–3239. [Google Scholar] [CrossRef]
  43. Roy, S.; Kabir, M.; Mondal, D.; Ali, I.K.M.; Petri, W.A.; Haque, R. Real-Time-PCR Assay for Diagnosis of Entamoeba Histolytica Infection. J. Clin. Microbiol. 2005, 43, 2168–2172. [Google Scholar] [CrossRef]
  44. Bansal, D.; Sehgal, R.; Chawla, Y.; Mahajan, R.C.; Malla, N. In Vitro Activity of Antiamoebic Drugs against Clinical Isolates of Entamoeba Histolytica and Entamoeba Dispar. Ann. Clin. Microbiol. Antimicrob. 2004, 3, 27. [Google Scholar] [CrossRef] [PubMed]
  45. Fujishima, T.; Nishise, S.; Ichihara, M.; Kobayashi, S.; Takeuchi, T. Difficulties in the Treatment of Intestinal Amoebiasis in Mentally Disabled Individuals at a Rehabilitation Institution for the Intellectually Impaired in Japan. Chemotherapy 2010, 56, 348–352. [Google Scholar] [CrossRef]
  46. Iyer, L.R.; Singh, N.; Verma, A.K.; Paul, J. Differential Expression and Immunolocalization of Antioxidant Enzymes in Entamoeba histolytica Isolates during Metronidazole Stress. BioMed Res. Int. 2014, 2014, 1–11. [Google Scholar] [CrossRef]
  47. Gazzinelli-Guimaraes, P.H.; Nutman, T.B. Helminth Parasites and Immune Regulation. F1000Research 2018, 7, 1685. [Google Scholar] [CrossRef]
  48. Saboyá, M.I.; Catalá, L.; Nicholls, R.S.; Ault, S.K. Update on the Mapping of Prevalence and Intensity of Infection for Soil-Transmitted Helminth Infections in Latin America and the Caribbean: A Call for Action. PLoS Neglected Trop. Dis. 2013, 7, e2419. [Google Scholar] [CrossRef] [PubMed]
  49. Strunz, E.C.; Addiss, D.G.; Stocks, M.E.; Ogden, S.; Utzinger, J.; Freeman, M.C. Water, Sanitation, Hygiene, and Soil-Transmitted Helminth Infection: A Systematic Review and Meta-Analysis. PLoS Med. 2014, 11, e1001620. [Google Scholar] [CrossRef]
  50. Greenland, K.; Dixon, R.; Khan, S.A.; Gunawardena, K.; Kihara, J.H.; Smith, J.L.; Drake, L.; Makkar, P.; Raman, S.; Singh, S.; et al. The Epidemiology of Soil-Transmitted Helminths in Bihar State, India. PLoS Neglected Trop. Dis. 2015, 9, e0003790. [Google Scholar] [CrossRef]
  51. González-Moreno, O.; Domingo, L.; Teixidor, J.; Gracenea, M. Prevalence and Associated Factors of Intestinal Parasitisation: A Cross-Sectional Study among Outpatients with Gastrointestinal Symptoms in Catalonia, Spain. Parasitol. Res. 2011, 108, 87–93. [Google Scholar] [CrossRef]
  52. Horton, J. Global Anthelmintic Chemotherapy Programs: Learning from History. Trends Parasitol. 2003, 19, 405–409. [Google Scholar] [CrossRef]
  53. Albonico, M.; Allen, H.; Chitsulo, L.; Engels, D.; Gabrielli, A.-F.; Savioli, L. Controlling Soil-Transmitted Helminthiasis in Pre-School-Age Children through Preventive Chemotherapy. PLoS Neglected Trop. Dis. 2008, 2, e126. [Google Scholar] [CrossRef] [PubMed]
  54. Jardim-Botelho, A.; Raff, S.; Rodrigues, R.D.; Hoffman, H.J.; Diemert, D.J.; Corrêa-Oliveira, R.; Bethony, J.M.; Gazzinelli, M.F. Hookworm, Ascaris Lumbricoides Infection and Polyparasitism Associated with Poor Cognitive Performance in Brazilian Schoolchildren. Trop. Med. Int. Health 2008, 13, 994–1004. [Google Scholar] [CrossRef]
  55. Stephenson, L.S.; Holland, C.V.; Cooper, E.S. The Public Health Significance of Trichuris Trichiura. Parasitology 2000, 121, S73–S95. [Google Scholar] [CrossRef]
  56. Pilotte, N.; Papaiakovou, M.; Grant, J.R.; Bierwert, L.A.; Llewellyn, S.; McCarthy, J.S.; Williams, S.A. Improved PCR-Based Detection of Soil Transmitted Helminth Infections Using a Next-Generation Sequencing Approach to Assay Design. PLoS Neglected Trop. Dis. 2016, 10, e0004578. [Google Scholar] [CrossRef]
  57. Keenan, J.D.; Hotez, P.J.; Amza, A.; Stoller, N.E.; Gaynor, B.D.; Porco, T.C.; Lietman, T.M. Elimination and Eradication of Neglected Tropical Diseases with Mass Drug Administrations: A Survey of Experts. PLoS Neglected Trop. Dis. 2013, 7, e2562. [Google Scholar] [CrossRef]
  58. Fenwick, A. Praziquantel: Do We Need Another Antischistosoma Treatment? Future Med. Chem. 2015, 7, 677–680. [Google Scholar] [CrossRef] [PubMed]
  59. Keiser, J.; Utzinger, J. Efficacy of Current Drugs against Soil-Transmitted Helminth Infections: Systematic Review and Meta-Analysis. JAMA 2008, 299, 1937–1948. [Google Scholar] [CrossRef] [PubMed]
  60. Liaskou, M.; Duggan, C.; Joynes, R.; Rosado, H.R. Pharmacy’s Role in Antimicrobial Resistance and Stewardship. Available online: https://pharmaceutical-journal.com/article/research/pharmacys-role-in-antimicrobial-resistance-and-stewardship (accessed on 24 June 2022).
  61. Balsom, C.; Pittman, N.; King, R.; Kelly, D. Impact of a Pharmacist-Administered Deprescribing Intervention on Nursing Home Residents: A Randomized Controlled Trial. Pharm. Weekbl. 2020, 42, 1153–1167. [Google Scholar] [CrossRef] [PubMed]
  62. Kassem, A.B.; Ghoneim, A.I.; Nounou, M.I.; El-Bassiouny, N.A. Community Pharmacists’ Needs, Education, and Readiness in Facing COVID-19: Actions & Recommendations in Egypt. Int. J. Clin. Pr. 2021, 75, e14762. [Google Scholar] [CrossRef]
  63. Moustafa, H.A.M.; Hamid, A.E.; Hassoub, G.; Kassem, A.B. Assessing the Impact of Critical Care Training on Pharmacy Students in Egypt: A Pre-Post Study. BMC Med. Educ. 2024, 24, 1504. [Google Scholar] [CrossRef]
  64. Kassem, A.B.; Al Meslamani, A.Z.; Elmaghraby, D.H.; Magdy, Y.; AbdElrahman, M.; Hamdan, A.M.E.; Mohamed Moustafa, H.A. The Pharmacists’ Interventions after a Drug and Therapeutics Committee (DTC) Establishment during the COVID-19 Pandemic. J. Pharm. Policy Pr. 2024, 17, 2372040. [Google Scholar] [CrossRef]
  65. Ekenga, V.; Bailey-Wheeler, J.; Hart, T.; Sarpong, D.; Earls, M. Patients’ Perception of Community Pharmacists as Healthcare Providers and Willingness to Participate in Pharmacist Services: A Pilot Study. J. Pharm. Health Serv. Res. 2018, 9, 297–300. [Google Scholar] [CrossRef]
  66. Kassem, A.B.; Abdelrahim, M.E.; Mousa, A.; Harun, A.; Al-husseini, H.; Khaled, S.; Elhadidy, M.; Ibrahim, O.M. The Screening of Diabetes, Obesity, and Hypertension Risks Associated with Hepatitis C Within the Egyptian Population in a Community Pharmacy Setting. J. Clin. Nurs. Res. 2022, 6, 31–42. [Google Scholar] [CrossRef]
  67. Thidrickson, D.; Goodyer, L. Pharmacy Travel Health Services in Canada: Experience of Early Adopters. Pharmacy 2019, 7, 42. [Google Scholar] [CrossRef] [PubMed]
  68. Abdel-Qader, D.H.; Saadi Ismael, N.; Al Meslamani, A.Z.; Albassam, A.; El-Shara’, A.A.; Lewis, P.J.; Hamadi, S.; Al Mazrouei, N. The Role of Clinical Pharmacy in Preventing Prescribing Errors in the Emergency Department of a Governmental Hospital in Jordan: A Pre-Post Study. Hosp. Pharm. 2021, 56, 681–689. [Google Scholar] [CrossRef] [PubMed]
  69. Arredondo, E.; Udeani, G.; Horseman, M.; Hintze, T.D.; Surani, S. Role of Clinical Pharmacists in Intensive Care Units. Cureus 2021, 13, e17929. [Google Scholar] [CrossRef] [PubMed]
  70. Al Meslamani, A.Z.; Kassem, A.B.; El-Bassiouny, N.A.; Ibrahim, O.M. An Emergency Plan for Management of COVID-19 Patients in Rural Areas. Int. J. Clin. Pr. 2021, 75, e14563. [Google Scholar] [CrossRef]
  71. Anderson, S. The State of the World’s Pharmacy: A Portrait of the Pharmacy Profession. J. Interprof. Care 2002, 16, 391–404. [Google Scholar] [CrossRef]
  72. Dineen-Griffin, S.; Garcia-Cardenas, V.; Rogers, K.; Vargas, C.; Williams, K.A.; Benrimoj, S.I. An Australian Minor Ailments Scheme: Evaluation of an Integrated Approach by Community Pharmacists and General Medical Practitioners; University of Technology Sydney: Sydney, Australia, 2019. [Google Scholar]
  73. Paudyal, V.; Watson, M.C.; Sach, T.; Porteous, T.; Bond, C.M.; Wright, D.J.; Cleland, J.; Barton, G.; Holland, R. Are Pharmacy-Based Minor Ailment Schemes a Substitute for Other Service Providers? A Systematic Review. Br. J. Gen. Pr. 2013, 63, e472–e481. [Google Scholar] [CrossRef]
  74. Steed, L.; Sohanpal, R.; Todd, A.; Madurasinghe, V.W.; Rivas, C.; Edwards, E.A.; Summerbell, C.D.; Taylor, S.J.; Walton, R.T. Community Pharmacy Interventions for Health Promotion: Effects on Professional Practice and Health Outcomes. Cochrane Database Syst. Rev. 2019, 12, CD011207. [Google Scholar] [CrossRef]
  75. Lalaye, D.; De Bruijn, M.E.; De Jong, T.P. Prevalence of Schistosoma Haematobium Measured by a Mobile Health System in an Unexplored Endemic Region in the Subprefecture of Torrock, Chad. JMIR Public Health Surveill. 2019, 5, e13359. [Google Scholar] [CrossRef]
  76. Garau, J.; Bassetti, M. Role of Pharmacists in Antimicrobial Stewardship Programmes. Int. J. Clin. Pharm. 2018, 40, 948–952. [Google Scholar] [CrossRef]
  77. Kusuma, I.Y.; Pratiwi, H.; Pitaloka, D.A.E. Role of Pharmacists in Antimicrobial Stewardship During COVID-19 Outbreak: A Scoping Review. J. Multidiscip. Health 2022, 15, 2605–2614. [Google Scholar] [CrossRef] [PubMed]
  78. Moustafa, H.A.M.; Kassem, A.B. COVID-19-Related Health Literacy and Preparedness to What May Come: A Cross-Sectional Study. Beni-Suef Univ. J. Basic Appl. Sci. 2023, 12, 114. [Google Scholar] [CrossRef]
  79. Parente, D.M.; Morton, J. Role of the Pharmacist in Antimicrobial Stewardship. Med. Clin. North. Am. 2018, 102, 929–936. [Google Scholar] [CrossRef]
  80. Adams, A.J.; Dering-Anderson, A. Pharmacy-Based Travel Health Services: State Approaches to Prescriptive Authority. J. Pharm. Technol. 2018, 34, 175–180. [Google Scholar] [CrossRef] [PubMed]
  81. Raczkiewicz, D.; Sarecka-Hujar, B.; Pawełczak-Barszczowska, A.; Bojar, I. How Do Polish Pharmacy Staff Evaluate Own Qualifications, Competences, Relevance, Motivation, Effectiveness in Health Promotion? Health Promot. Int. 2022, 37, daab043. [Google Scholar] [CrossRef]
  82. Gatewood, S.B.S.; Stanley, D.D.; Goode, J.-V.K.R. Implementation of a Comprehensive Pretravel Health Program in a Supermarket Chain Pharmacy. J. Am. Pharm. Assoc. 2009, 49, 660–669. [Google Scholar] [CrossRef]
  83. Cohen, A. Role of the European Pharmacist in the Implementation of the Latest WHO Guidelines for Malaria. Pathogens 2023, 12, 729. [Google Scholar] [CrossRef] [PubMed]
  84. Molyneux, D. Neglected Tropical Diseases. Community Eye Health 2013, 26, 21–24. [Google Scholar]
  85. Research Randomizer. Available online: https://randomizer.org/ (accessed on 15 June 2024).
  86. da Silva, J.V.L.; Fontes, G.; Dos Santos, C.D.; Dos Santos, R.V.; da Rocha, E.M.M. Factors Associated with Gastrointestinal Parasitic Infections among Young Population in Northeast Brazil. Can. J. Infect. Dis. Med. Microbiol. 2016, 2016, 6239434. [Google Scholar] [CrossRef]
  87. Gil, F.F.; Busatti, H.G.N.O.; Cruz, V.L.; Santos, J.F.G.; Gomes, M.A. High Prevalence of Enteroparasitosis in Urban Slums of Belo Horizonte-Brazil. Presence of Enteroparasites as a Risk Factor in the Family Group. Ann. Trop. Med. Parasitol. 2013, 107, 320–324. [Google Scholar] [CrossRef]
  88. Japa, I.; Ancha, B.; Custodio, A.; Ohrenschall, R.; Cordero, R.; Deverlis, A.; Chapman, J.; Hickson, M.R.; Steenhoff, A.P.; Lowenthal, E.D. Effectiveness of Deworming with Single-Dose Albendazole for Preschool-Aged Children in the Dominican Republic. Glob. Pediatr. Health 2021, 8, 2333794X211002949. [Google Scholar] [CrossRef]
  89. Pickering, A.J.; Njenga, S.M.; Steinbaum, L.; Swarthout, J.; Lin, A.; Arnold, B.F.; Stewart, C.P.; Dentz, H.N.; Mureithi, M.; Chieng, B.; et al. Effects of Single and Integrated Water, Sanitation, Handwashing, and Nutrition Interventions on Child Soil-Transmitted Helminth and Giardia Infections: A Cluster-Randomized Controlled Trial in Rural Kenya. PLoS Med. 2019, 16, e1002841. [Google Scholar] [CrossRef]
  90. Belo, V.S.; de Oliveira, R.B.; Fernandes, P.C.; Nascimento, B.W.L.; Fernandes, F.V.; Castro, C.L.F.; dos Santos, W.B.; da Silva, E.S. Factors Associated with Intestinal Parasitosis in a Population of Children and Adolescents. Rev. Paul. Pediatr. 2012, 30, 195–201. [Google Scholar] [CrossRef]
  91. Frei, F.; Juncansen, C.; Ribeiro-Paes, J.T. Levantamento epidemiológico das parasitoses intestinais: Viés analítico decorrente do tratamento profilático. Cad. Saúde Pública 2008, 24, 2919–2925. [Google Scholar] [CrossRef] [PubMed]
  92. Ayabina, D.V.; Clark, J.; Bayley, H.; Lamberton, P.H.L.; Toor, J.; Hollingsworth, T.D. Gender-Related Differences in Prevalence, Intensity and Associated Risk Factors of Schistosoma Infections in Africa: A Systematic Review and Meta-Analysis. PLoS Neglected Trop. Dis. 2021, 15, e0009083. [Google Scholar] [CrossRef] [PubMed]
  93. Salem, S.; Mitchell, R.E.; El-Alim El-Dorey, A.; Smith, J.A.; Barocas, D.A. Successful Control of Schistosomiasis and the Changing Epidemiology of Bladder Cancer in Egypt. BJU Int. 2011, 107, 206–211. [Google Scholar] [CrossRef]
  94. Barakat, R.M.R. Epidemiology of Schistosomiasis in Egypt: Travel through Time: Review. J. Adv. Res. 2013, 4, 425–432. [Google Scholar] [CrossRef]
  95. Gyorkos, T.W.; Maheu-Giroux, M.; Blouin, B.; Saavedra, L.; Casapía, M. Efficacy of a single dose of Albendazole for soil-transmitted helminth infections in school children of a village in Iquitos, Perú. Rev. Peru. Med. Exp. Salud Publica 2013, 30, 601–607. [Google Scholar]
  96. Pullan, R.L.; Halliday, K.E.; Oswald, W.E.; Mcharo, C.; Beaumont, E.; Kepha, S.; Witek-McManus, S.; Gichuki, P.M.; Allen, E.; Drake, T.; et al. Effects, Equity, and Cost of School-Based and Community-Wide Treatment Strategies for Soil-Transmitted Helminths in Kenya: A Cluster-Randomised Controlled Trial. Lancet 2019, 393, 2039–2050. [Google Scholar] [CrossRef]
  97. Loker, E.S. This De-Wormed World? J. Parasitol. 2013, 99, 933–942. [Google Scholar] [CrossRef]
  98. Clarke, N.E.; Clements, A.C.A.; Doi, S.A.; Wang, D.; Campbell, S.J.; Gray, D.; Nery, S.V. Differential Effect of Mass Deworming and Targeted Deworming for Soil-Transmitted Helminth Control in Children: A Systematic Review and Meta-Analysis. Lancet 2017, 389, 287–297. [Google Scholar] [CrossRef]
  99. Shawn McFarland, M.; Wallace, J.P.; Parra, J.; Baker, J. Evaluation of Patient Satisfaction with Diabetes Management Provided by Clinical Pharmacists in the Patient-Centered Medical Home. Patient 2014, 7, 115–121. [Google Scholar] [CrossRef] [PubMed]
  100. Sherrill, C.H.; Cavanaugh, J.; Shilliday, B.B. Patient Satisfaction with Medicare Annual Wellness Visits Administered by a Clinical Pharmacist Practitioner. J. Manag. Care Spec. Pharm. 2017, 23, 1125–1129. [Google Scholar] [CrossRef]
  101. Yuliandani, Y.; Alfian, S.D.; Puspitasari, I.M. Patient Satisfaction with Clinical Pharmacy Services and the Affecting Factors: A Literature Review. Pharmacia 2022, 69, 227–236. [Google Scholar] [CrossRef]
  102. Abaza, S.M. Treatment of Schistosomiasis: From Praziquantel to Development of New Drug Targets. PUJ 2013, 6, 127–148. [Google Scholar]
  103. Elmorshedy, H.; Bergquist, R.; El-Ela, N.E.A.; Eassa, S.M.; Elsakka, E.E.; Barakat, R. Can Human Schistosomiasis Mansoni Control Be Sustained in High-Risk Transmission Foci in Egypt? Parasites Vectors 2015, 8, 372. [Google Scholar] [CrossRef]
  104. Tran, D.; Gatewood, S.; Moczygemba, L.R.; Stanley, D.D.; Jean-Venable, R.G. Evaluating Health Outcomes Following a Pharmacist-Provided Comprehensive Pretravel Health Clinic in a Supermarket Pharmacy. J. Am. Pharm. Assoc. 2015, 55, 143–152. [Google Scholar] [CrossRef]
  105. Hind, C.; Bond, C.; Lee, A.J.; van Teijlingen, E. Travel Medicine Services from Community Pharmacy: Evaluation of a Pilot Service. Available online: https://pharmaceutical-journal.com/article/research/travel-medicine-services-from-community-pharmacy-evaluation-of-a-pilot-service (accessed on 12 June 2024).
Figure 1. Types of drugs used.
Figure 1. Types of drugs used.
Tropicalmed 10 00215 g001
Figure 2. Stacked bar chart showing the effect of patient counseling on infection recurrence and personal hygiene. *: statistically significant (p < 0.05).
Figure 2. Stacked bar chart showing the effect of patient counseling on infection recurrence and personal hygiene. *: statistically significant (p < 0.05).
Tropicalmed 10 00215 g002
Table 1. Demographic and clinical characteristics of participants (N = 173).
Table 1. Demographic and clinical characteristics of participants (N = 173).
ParameterN (%)
Age, years
0–547 (27.2%)
6–1146 (26.6%)
12–1829 (16.8%)
>1851 (29.5%)
Gender
Female92 (53.2%)
Male81 (46.8%)
Type of infection
Oxyuris77 (44.5%)
Entamoeba50 (28.9%)
Entamoeba Cyst15 (8.7%)
Ascaris15 (8.7%)
Schistosomiasis5 (2.9%)
Giardia8 (4.6%)
Pinworm3 (1.7%)
Personal hygiene
Yes71 (41%)
No102 (59%)
Patient counseling
Yes96 (55.5%)
No77 (44.5%)
Dose repeat
Yes119 (68.8%)
No54 (31.2%)
Recurrence
Yes101 (58.4%)
No72 (41.6%)
Data is represented as a number (percentage).
Table 2. Factors affecting recurrence (N = 173).
Table 2. Factors affecting recurrence (N = 173).
ParameterRecurrencep Value
YesNo
Age, years 0.002 *
0–526 (55.3%)21 (44.7%)
6–1135 (76.1%)11 (23.9%)
12–1820 (69.0%)9 (31.0%)
>1820 (39.2%) 31 (60.8%)
Gender 0.402
Female51 (55.4%)41 (44.6%)
Male50 (61.7%)31 (38.8%)
Type of infection 0.018 *
Oxyuris41 (53.2%)36 (46.8%)
Entamoeba34 (68.0%)16 (32.0%)
Entamoeba Cyst7 (46.7%)8 (53.3%)
Ascaris7 (46.7%)8 (53.3%)
Schistosomiasis1 (20.0%)4 (80.0%)
Giardia8 (100%)0 (0%)
Pinworm3 (100%)0 (0%)
Personal hygiene <0.001 *
Yes16 (22.5%)55 (77.5%)
No85 (83.3%)17 (16.7%)
Patient counseling <0.001 *
Yes29 (30.2%)67 (69.8%)
No72 (93.5%)5 (6.5%)
Dose repeat 0.132
Yes74 (62.2%)45 (37.8%)
No27 (50.0%)27 (50.0%)
Values are presented as n (column %). For each variable, the distribution of categories between patients with recurrence (“Yes”) and without recurrence (“No”) was compared using Pearson’s Chi-square test (two-tailed); p-values < 0.05 are considered statistically significant and are flagged with *. Reference category for each comparison: Age > 18 years, male sex, Oxyuris infection, “Yes” to personal hygiene, “Yes” to patient counseling, and “Yes” to repeat dose. These categories were used as the baseline when calculating Chi-square residuals. This was an exploratory analysis; therefore, no adjustment for multiple testing was applied.
Table 3. Relationship between patient counseling and personal hygiene.
Table 3. Relationship between patient counseling and personal hygiene.
Personal Hygiene
Patient CounselingYesNop Value
Yes68 (70.8%)28 (29.2%)<0.001 *
No3 (3.9%)74 (96.1%)
Data is represented as a number (percentage). * Statistically significant association using Chi-square test p < 0.05.
Table 4. Evaluation of factors affecting infection recurrence rate using logistic regression.
Table 4. Evaluation of factors affecting infection recurrence rate using logistic regression.
VariableCoefficientOdds Ratiop Value
Age
    6–11 (Ref) 0.276
    0–5−0.3010.7400.625
    12–18−0.1170.8900.881
    >18−1.2400.2890.086
Gender0.1011.1060.828
Type of Infection
    Schistosomiasis (Ref) 0.979
    Oxyuris0.6901.9940.621
    Entamoeba1.1653.2070.402
    Entamoeba cyst1.0922.9800.451
    Ascaris0.8462.3310.573
    Giardia18.7914,5860.999
    Pinworm18.6812,9720.999
Personal Hygiene1.5164.5540.004 *
Patient Counselling2.53612.624<0.001 *
Dose Repeat−0.7240.4850.238
Constant−1.5210.2180.313
* Statistically significant association between factor and infection recurrence using logistic regression p < 0.05.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kassem, A.B.; Al Meslamani, A.Z.; AbdElrahman, M.; Al Mazrouei, N.; Okda, S.M.; El-Bassiouny, N.A.; Hamedo, A.A.-h.; Shaban, D.A.; Elsmadessy, D.F.; Binsaleh, A.Y.; et al. The Impact of a Community Pharmacy-Led Deworming-Related Counselling Service: An Interventional Study in a Low-to-Middle Income Country. Trop. Med. Infect. Dis. 2025, 10, 215. https://doi.org/10.3390/tropicalmed10080215

AMA Style

Kassem AB, Al Meslamani AZ, AbdElrahman M, Al Mazrouei N, Okda SM, El-Bassiouny NA, Hamedo AA-h, Shaban DA, Elsmadessy DF, Binsaleh AY, et al. The Impact of a Community Pharmacy-Led Deworming-Related Counselling Service: An Interventional Study in a Low-to-Middle Income Country. Tropical Medicine and Infectious Disease. 2025; 10(8):215. https://doi.org/10.3390/tropicalmed10080215

Chicago/Turabian Style

Kassem, Amira B., Ahmad Z. Al Meslamani, Mohamed AbdElrahman, Nadia Al Mazrouei, Sherouk M. Okda, Noha A. El-Bassiouny, Asmaa Abdel-hamed Hamedo, Doaa Abdelrazek Shaban, Dina Fathy Elsmadessy, Ammena Y. Binsaleh, and et al. 2025. "The Impact of a Community Pharmacy-Led Deworming-Related Counselling Service: An Interventional Study in a Low-to-Middle Income Country" Tropical Medicine and Infectious Disease 10, no. 8: 215. https://doi.org/10.3390/tropicalmed10080215

APA Style

Kassem, A. B., Al Meslamani, A. Z., AbdElrahman, M., Al Mazrouei, N., Okda, S. M., El-Bassiouny, N. A., Hamedo, A. A.-h., Shaban, D. A., Elsmadessy, D. F., Binsaleh, A. Y., Saleh, A., & Moustafa, H. A. M. (2025). The Impact of a Community Pharmacy-Led Deworming-Related Counselling Service: An Interventional Study in a Low-to-Middle Income Country. Tropical Medicine and Infectious Disease, 10(8), 215. https://doi.org/10.3390/tropicalmed10080215

Article Metrics

Back to TopTop